Skip to content
Screener

Common Stock at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$0-100%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$2.43B+65.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$6K+20.0%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$48K+29.7%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$560M0.0%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
220M0.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$96.9M-27.4%
Net income-$83.7M-17.7%
EPS (diluted)-$2.87+13.3%

Balance sheet

See full
Cash & equivalents$474.8M+201%
Total debt$1.1M+44.0%
Total equity$1.3B+232%
Total assets$1.4B+207%

Cash flow

See full
Operating cash flow-$77.5M-41.8%
CapEx$245.0K+338%
Free cash flow-$77.8M-42.1%

Valuation

See full
Market cap$8.9B+770%
Enterprise value$8.43B+873%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-38.9%-10.3pp
Debt / equity0.0×
Current ratio15.7×+9.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001689548-26-000083
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value; 150,000,000 shares authorized; 27,916,593 shares issued and outstanding as of June 30, 2026, and 25,195,092 shares issued and outstanding as of December 31, 20251515
Additional paid-in capital2,659,9902,017,566
Accumulated deficit(1,316,289)(1,140,008)
Accumulated other comprehensive (loss) gain(2,672)563
Total stockholders’ equity1,341,044878,136

Item 1. Financial Statements (Unaudited)

FAQ

What is Praxis Precision Medicines, Inc.'s common stock?
Praxis Precision Medicines, Inc. (PRAX) reported common stock of 150M in Q2 2026.
How has Praxis Precision Medicines, Inc.'s common stock changed year-over-year?
Praxis Precision Medicines, Inc.'s common stock decreased by 0.0% year-over-year, from 150M to 150M.
What is the long-term trend for Praxis Precision Medicines, Inc.'s common stock?
Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s common stock has grown at a 721.9% compound annual growth rate (CAGR), from 4K to 150M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Praxis Precision Medicines, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude